Case Report: Clinical Experience of Treating Pembrolizumab-induced Systemic Capillary Leak Syndrome (SCLS) in One Patient with Metastatic Gastroesophageal Junction Squamous Cell Carcinoma

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2023 Sep 25

PMID 37746555

Authors

Hua Ni

Xinjia Ding

Shikai Wu

Xuan Jin

Affiliations

Soon will be listed here.

Abstract

Systemic capillary leak syndrome (SCLS) is a rare and complex adverse effect of immune checkpoint inhibitors (ICIs). The diagnosis of drug-induced SCLS is based on diffuse infusions of exudative fluid into the interstitial areas and the exclusion of other causes. The best management of ICIs-induced SCLS is not settled, though proper supportive care and corticosteroids were commonly applied as the first-line treatment. In our patient with advanced gastroesophageal junction squamous cell carcinoma, although ICIs-induced SCLS was successfully controlled with corticosteroids, the patient soon experienced cancer progress and died of pulmonary infections. Based on our experience and the reported cases by other hospitals, different stages of SCLS might respond differently to the same treatment. Therefore, a grading of ICIs-induced SCLS might help to stratify the patient for different treatment strategies. Besides, corticosteroids-sensitive patients, though waived from deadly SCLS, might be at higher risk of cancer progress and subsequent infections due to the application of corticosteroids. Considering that the inflammatory factors should be closely involved in the development of ICIs-induced SCLS, targeted therapy against the driver inflammatory cytokine might offer treatment regimens that are more effective and safer.

Citing Articles

Systemic capillary leak syndrome.

Druey K, Arnaud L, Parikh S Nat Rev Dis Primers. 2024; 10(1):86.

PMID: 39543164 DOI: 10.1038/s41572-024-00571-5.

References

Abdel-Wahab N, Shah M, Suarez-Almazor M . Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016; 11(7):e0160221. PMC: 4966895. DOI: 10.1371/journal.pone.0160221. View

Jolles S, Sewell W, Misbah S . Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005; 142(1):1-11. PMC: 1809480. DOI: 10.1111/j.1365-2249.2005.02834.x. View

Percik R, Nethanel A, Liel Y . Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment. Immunotherapy. 2021; 13(8):653-659. DOI: 10.2217/imt-2020-0332. View

Izzedine H, Mathian A, Amoura Z, Ng J, Jhaveri K . Anticancer Drug-Induced Capillary Leak Syndrome. Kidney Int Rep. 2022; 7(5):945-953. PMC: 9091576. DOI: 10.1016/j.ekir.2022.02.014. View

Marin A, Deitz G, Mudie L, Reddy A, Palestine A . Bilateral choroidal effusions and angle closure in the setting of systemic capillary leak syndrome from HLA-directed vaccine and pembrolizumab therapy for squamous cell carcinoma. Am J Ophthalmol Case Rep. 2022; 29:101777. PMC: 9791606. DOI: 10.1016/j.ajoc.2022.101777. View

Qin H, Vlaminck B, Owoyemi I, Herrmann S, Leung N, Markovic S . Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction. Mayo Clin Proc Innov Qual Outcomes. 2021; 5(3):670-674. PMC: 8240169. DOI: 10.1016/j.mayocpiqo.2021.01.004. View

Jeong G, Lee K, Lee I, Oh J, Kim D, Shin J . Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(2). PMC: 6406478. DOI: 10.3390/jcm8020143. View

Dhir V, Arya V, Malav I, Suryanarayanan B, Gupta R, Dey A . Idiopathic systemic capillary leak syndrome (SCLS): case report and systematic review of cases reported in the last 16 years. Intern Med. 2007; 46(12):899-904. DOI: 10.2169/internalmedicine.46.6129. View

Umeda Y, Hayashi H, Sugiyama S, Aoyama Y . Systemic capillary leak syndrome triggered by anti-programmed death 1 checkpoint inhibitor in psoriasis. J Dermatol. 2020; 47(11):1322-1325. DOI: 10.1111/1346-8138.15541. View

10.

Siddall E, Khatri M, Radhakrishnan J . Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017; 92(1):37-46. DOI: 10.1016/j.kint.2016.11.029. View

11.

Lambert M, Launay D, Hachulla E, Morell-Dubois S, Soland V, Queyrel V . High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Crit Care Med. 2008; 36(7):2184-7. DOI: 10.1097/CCM.0b013e31817d7c71. View

12.

Clarkson B, Thompson D, HORWITH M, LUCKEY E . Cyclical edema and shock due to increased capillary permeability. Am J Med. 1960; 29:193-216. DOI: 10.1016/0002-9343(60)90018-8. View

13.

Yabe H, Yabe M, Koike T, Shimizu T, Morimoto T, Kato S . Rapid improvement of life-threatening capillary leak syndrome after stem cell transplantation by bevacizumab. Blood. 2010; 115(13):2723-4. DOI: 10.1182/blood-2009-11-247056. View

14.

De Chambrun M, Gousseff M, Mauhin W, Lega J, Lambert M, Riviere S . Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. Am J Med. 2017; 130(10):1219.e19-1219.e27. DOI: 10.1016/j.amjmed.2017.05.023. View

15.

Lescure C, Lescoat A, Sale A, Bazin Y, Duverge L, Desrues B . Systemic Capillary Leak Syndrome (Clarkson's Disease) as a Complication of Anti-Programmed Death 1 Immunotherapy. J Thorac Oncol. 2019; 14(6):e131-e132. DOI: 10.1016/j.jtho.2019.02.003. View